Astera Labs posts Q3 2025 results update

Astera Labs, Inc. filed a current report to let investors know it has released a press release with its financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Astera Labs, Inc. filed a current report to let investors know it has released a press release with its financial results for the quarter ended September 30, 2025. The company furnished this press release, dated November 4, 2025, as Exhibit 99.1, meaning it is provided for information but is not treated as formally filed under certain liability provisions of the securities laws. The report is signed on behalf of Astera Labs by Chief Financial Officer Michael Tate.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Astera Labs (ALAB) report in this SEC 8-K filing?

Astera Labs, Inc. reported that it issued a press release with its financial results for the quarter ended September 30, 2025, and furnished that press release as Exhibit 99.1.

Which period do the latest Astera Labs (ALAB) financial results cover?

The financial results described in the press release furnished by Astera Labs cover the quarter ended September 30, 2025.

When did Astera Labs (ALAB) issue the press release with its quarterly results?

Astera Labs issued the press release with its quarterly financial results on November 4, 2025.

How were Astera Labs (ALAB) Q3 2025 results provided to investors?

Astera Labs provided its Q3 2025 financial results through a press release that is furnished, rather than filed, as Exhibit 99.1 to this current report.

Who signed the Astera Labs (ALAB) current report about Q3 2025 results?

The current report regarding the press release for the quarter ended September 30, 2025, was signed on behalf of Astera Labs, Inc. by Chief Financial Officer Michael Tate.

What exhibits are included with this Astera Labs (ALAB) 8-K?

The report includes Exhibit 99.1, the press release dated November 4, 2025, and Exhibit 104, the cover page interactive data file with embedded Inline XBRL tags.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/04/2025 - 04:09 PM EST Learn about SEC filing dates

false000173629700017362972025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

Astera Labs, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41979

82-3437062

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2345 North First Street,

San Jose, CA 95131

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (408) 766-3806

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐									Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐									Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐									Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐									Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

ALAB

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 2.02    Results of Operations and Financial Condition

On November 4, 2025, Astera Labs, Inc. (the "Company") issued a press release regarding its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description of Exhibit

99.1

Press release issued by Astera Labs, Inc. dated November 4, 2025.

104

Cover Page Interactive Data File (Cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 4, 2025

Astera Labs, Inc.

By: /s/ Michael Tate

Name: Michael Tate

Title: Chief Financial Officer